Publications du Dr David Fortin

Drapeau A, Poirier MB, Madugundu GS, Wagner RJ, Fortin D: IntraarterialTemozolomide, Osmotic Blood-Brain Barrier Disruption andRadiotherapy in a Rat F98-Glioma Model Clinical Cancer Drugs, 2017,4, 000-000 (in publication)

Garyfallidisa E, Côté MA, Rheault F, Sidhub J, Hauc J, Petit L ,FortinD , Cunannee S , Descoteaux M : Recognition of White Matter BundlesUsing Local and Global Streamline-Based Registration and Clustering.',2017 <>

Chamberland M, Girard G, Bernier M, Fortin D, Descoteaux M,Whittingstall K:On the Origin of Individual Functional Connectivity Variability: the Role of White Matter Architecture.', 2017 <>

Chamberland M, Girard G, Bernier M, Fortin D, Descoteaux M,Witthingstall K. On the Origin of Individual Functional ConnectivityVariability: the Role of White Matter Architecture.', 7 (2017), >491-503 <>>

Iorio-Morin, Ahmed, Bidger... Fortin D. Demographics, Interests, andQuality of Life of Canadian Neurosurgery Residents, 2017, 1-7 

Kameda-Smith, Iorio Morin, ...Fortin D. Smartphone Usage Patternsby Canadian Neurosurgery Residents: a National Cross-SectionalSurvey.', 2017 <> >

Chamberland M, Scherrer B, Prabhu SP, Madsen J, Fortin D,Whittingstall K, Descoteaux M, Warfield SK. Active Delineation ofMeyer's Loop Using Oriented Priors Through MAGNEtic Tractography(MAGNET). 38 (2017), 509-27 < 

Desmarais G, Charest G, Therriault H, She M, Fortin D, Bujold R,Mathieu D, Paquetteb. Infiltration of F98 Glioma Cells in Fischer RatBrain Is Temporary Stimulated by Radiation, 92 (2016), 444-50  < 

Ghumman S, Fortin D, Noel-Lamy M, Cunnane SC, Witthingstall K.Exploratory Study of the Effect of Brain Tumors on the Default ModeNetwork, 128 (2016), 437-44 < 

She M, Fortin D, Paquette B, Sanche L. Convection-EnhancementDelivery of Liposomal Formulation of Oxaliplatin Shows Less ToxicityThan Oxaliplatin Yet Maintains a Similar Median Survival Time in F98Glioma-Bearing Rat Model, 34 (2016), 269-76 < 

Iorio-Morin C, Fortin D, Blanchard J. TBI Prognosis Calculator: aMobile Application to Estimate Mortality and Morbidity FollowingTraumatic Brain Injury, 142 (2016), 48-53 < 

Chamberland M, Bernier M, Fortin D, Whittingstall K, Descoteaux M.3D interactive tractography-informed resting-state fMRI connectivity(2015). Front Neursci 9, 275.

Tax CMW, Chamberland M, Van Stralen M, Veirgever MA, WhittingstallK, Fortin D, Descoteaux M, Leemans A. Seeing More by ShowingLess: Orientation-Dependent Transparency Rendering for FiberTractography Visualization (2015). PLos ONE 10 (10), e0139434.

Shi M, Fortin D, Sanche L, Paquette B. Convection-enhancementdelivery of platinum-based drugs and Lipoplatin(TM) to optimize theconcomitant effect with radiotherapy in F98 glioma rat model (2015).Invest New Drugs 33, 555-563.

Drapeau A, Fortin D. Chemotherapy Delivery Strategies to the CentralNervous System: neither Optional nor Superfluous (2015) Curr DrugTargets 15, 9, 752-768.

Desmarais G, Chares G, Fortin D, Paquette B. Cyclooxygenase-2inhibitor prevents radiation-enhanced infiltration of F98 glioma cells inbrain of Fischer rat (2015). Int J Radiol Biol. 91, 624-633.

Roy LR, Poirier MB, Fortin D. Chloroquine inhibits the malignantphenotype of glioblastoma partially by suppressing TGF-beta (2015).Invest New Drug 33, 1020-1031.

Fortin D, Morin PA, Belzile F, Mathieu D, Paré FM. (2014) Intra-arterialcarboplatin as a salvage strategy in the treatment of recurrentglioblastoma multiforme. J Neurooncol. 119(2):397-403.

Whittingstall K, Bernier M, Houde JC, Fortin D, Descoteaux M. (2014)Structural pathways underlying visuospatial processing in humans.Cortex. 56:85-98.

Roy LO, Poirier MB, Fortin D. Transforming growth factor-beta and itsimplication in the malignancy of gliomas. Target Oncol. Accepted onFeb 2014 : DOI 10.1007/s11523-014-0308-y.

Blanchette M, Tremblay L, Lepage M, Fortin D. (2014) Impact of DrugSize on Brain Tumor and Brain Parenchyma Delivery following a Blood-Brain Barrier Disruption. J Cereb Blood Flow Metab. 34(5):820-6.

Gadji M, Crous-Tsanaclis AM, Mathieu D, Mai S, Fortin D, Drouin R. Anew der(1;7)(q10;p10) leading to a singular 1p loss in a caseof glioblastoma with oligodendroglioma component.Neuropathology. 2013 Sep 30. doi: 10.1111/neup.12060.

Charest G, Sanche L, Fortin D, Mathieu D, Paquette B. Optimizationof the route of platinum drugs administration to optimize theconcomitant treatment with radiotherapy for glioblastomaimplanted in the Fischer rat brain. J Neurooncol. 2013 Dec;115(3):365-73. doi: 10.1007/s11060-013-1238-8.

Daigle K, Fortin D, Mathieu D, Saint-Pierre AB, Paré FM, de laSablonnière A, Goffaux P. Effects of surgical resection on theevolution of quality of life in newly diagnosed patients withglioblastoma: a report on 19 patients surviving to follow-up.Curr Med Res Opin. 2013 Oct;29(10):1307-13. doi:10.1185/03007995.2013.823858. Epub 2013 Jul 30.

Côté J, Savard M, Neugebauer W, Fortin D, Lepage M, Gobeil F. Dualkinin B1 and B2 receptor activation provides enhanced bloodbrainbarrier permeability and anticancer drug delivery intobrain tumors. Cancer Biol Ther. 2013 Jun 14;14(9). [Epub ahead ofprint]

Fortin, D., Aubin-Lemay, C., Boré, A., Girard, G., Houde, J.-C.,Whittingstall, K., &Descoteaux, M. (2012). Tractography in thestudy of the human brain: a neurosurgical perspective. TheCanadian Journal of Neurological Sciences Le Journal Canadien DesSciences Neurologiques, 39(6), 747-756.

Fortin, D. (2012). The blood-brain barrier: its influence in thetreatment of brain tumors metastases. Current Cancer DrugTargets, 12(3), 247-259.

Montagne M, Beaudoin N, Fortin D, Lavoie CL, Klinck R, Lavigne P. TheMax b-HLH-LZ can transduce into cells and inhibit c-Myctranscriptional activities. PLoS One. 2012;7(2):e32172. Epub 2012Feb 22.

Dea, N., Fournier-Gosselin, M.-P., Mathieu, D., Goffaux, P., & Fortin, D.(2012). Does extent of resection impact survival in patientsbearing glioblastoma? The Canadian Journal of NeurologicalSciences Le Journal Canadien Des Sciences Neurologiques, 39(5),632-637.

Desmarais G, Fortin D, Bujold R, Wagner R, Mathieu D, Paquette B(2012) Infiltration of glioma cells in brain parenchymastimulated by radiation in the F98/Fischer rat model. Int JRadiat Biol 88: 565-574

COTE J, SAVARD M, BOVENZI V, TREMBLAY L, GOBEIL F jr., LEPAGE M,FORTIN D (2012) Induction of selective blood-tumor barrierpermeability and macromolecular transport by a biostable kininB1 receptor agonist in a glioma rat model. PLoS One.2012;7(5):e37485.Epub 2012 May 21.

Charest, G., Sanche, L., Fortin, D., Mathieu, D., & Paquette, B. (2012).Glioblastoma Treatment: Bypassing the Toxicity of PlatinumCompounds by Using Liposomal Formulation and IncreasingTreatment Efficiency with Concomitant Radiotherapy.International Journal ofRadiation Oncology* Biology* Physics. doi:10.1016/j.ijrobp.

Blanchette M, Michaud K, Fortin D. A new method of quantitativelyassessing the opening of the blood-brain barrier in murineanimal models. J Neurosci Methods. 2012 Jun 15;207(2): 125-9.Epub 2012 Apr 12.

Fortin D: Temozolomide and the blood-brain barrier: itsinfluence in the treatment of primary brain tumors. expert reportcommissioned by Merck Forst, 2011.

Fortin D:The blood-brain barrier: its influence in the treatmentof brain tumors metastases. CCDT (in press), 2011.

Dea N, Borduas M, Kenny B, Fortin D, Mathieu D: Safety and efficacyof Gamma Knife radiosurgery for brain metastases in eloquentlocations. J Neurosurg (in press) 2011.

Goffaux P, Fortin D: Brain tumor headaches: From bedside tobench. Neurosurgery 67:459-466, 2010.

Bellavance MA, Poirier MB, Fortin D: Uptake and intracellularrelease kinetics of liposome formulations in glioma cells. Int JPharmaceutics 395:251-259, 2010.

Veilleux N, Goffaux P, Boudrias, Mathieu D, Daigle K, Fortin D: Qualityof life in neuro-oncology: age matters. J Neurosurg 113(2):325-332, 2010.

Charest G, Paquette B, Fortin D, Mathieu D, Sanche L: Concomitanttreatment of F98 glioma cells with new liposomal platinumcompounds and ionizing radiation. J Neurooncol 97:187-193,2010.

Côté J, Savard M, Bovenzi V, Dubuc C, Tremblay L, TsanaclisAM, Lepage M, Fortin D, Gobeil F: SELECTIVE TUMOR BLOODBRAINBARRIER OPENING WITH THE KININ B2 RECEPTORAGONIST [Phe8ψ(CH2NH)Arg9]-BK IN A F98 GLIOMA RATMODEL: AN MRI STUDY Neuropeptides 44(2):177-185, 2010.

Gadji M, Fortin D, Tsanaclis AM, Garini Y, Katzir N, Wienburg Y, Yan J,Klewes L, Klonish T, Drouin R, Mai S. Three-dimensional nucleartelomere architecture is associated with differential time toprogression and overall survival in glioblastoma patients.Neoplasia 12:183-191, 2010.

Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, Drouin R,Klonisch T. EGF receptor inhibitors in the treatment ofglioblastoma multiform: Old clinical allies and newly emergingtherapeutic concepts. Eur J Pharmacol 625:23-30, 2009.

Gadji M, Fortin D, Tsanaclis AM, Drouin R. Is the 1p/19q deletion adiagnostic marker of oligodendrogliomas? Cancer Genet.Cytogenet 194:12-22, 2009.

Charest G, Mathieu D, Lepage M, Fortin D, Paquette B, Sanche L:Polymer gel in rat skull to assess the accuracy of a new ratstereotactic device for use with the Gamma Knife. Acta Neurochir151:677-684, 2009.

Blanchette M, Pellerin M, Tremblay L, Lepage M, Fortin D: Real timemonitoring of Gd-DTPA during osmotic blood brain barrierdisruption using MRI in normal Wistar rats. Neurosurgery65:344-351, 2009

Goffaux P, Boudrias M, Mathieu D, Charpentier C, Veilleux N, Fortin D:Development and validation of a concise quality of lifequestionnaire for patients with brain tumors. CJNS vol. 36 (3)pp. 340-348, 2009.

Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Fortin, Kenny B,Michaud K, Mongia S, Niranjan A, Lunsford LD. Tumor bedradiosurgery after resection of cerebral metastases.Neurosurgery 62:817-824, 2008.

Bellavance MA, Blanchette M, Fortin D: Recent advances in bloodbrainbarrier disruption as a CNS delivery strategy. AAPS Journal10:166-177, 2008.

Jahnke K, Kraemer DF, Knight K, Fortin D, Bell S, Doolittle ND,Muldoon LL, Neuwelt EA : Intraarterial chemotherapy and osmoticblood-brain barrier disruption for patients with embryonal andgerm cell tumors of the CNS. Cancer Published online Dec 2007, inadavce of print.

Mathieu D, Fortin D: Chemotherapy and delivery in the treatmentof primary brain tumors. Current clinical pharmacology 2:197-211,2007.

Mathieu D, Lecomte R, Tsanaclis AM. Larouche A, Fortin D:Standardization and detailed characterization of the syngeneicFischer/F98 glioma model. Can J Neurol Sci 34: 296-306, 2007.

Fortin D, Gendron C, Boudrias M, Garant MP: Enhancedchemotherapy delivery by intra-arterial infusion and bloodbrainbarrier disruption in the treatment of cerebral metastasis.Cancer 109:751-760, 2007.

Mathieu D, Fortin D : The role of chemotherapy in the treatmentof malignant astrocytomas. Can J Neurol Sci 33 :127-140, 2006.

Blanchard J, Mathieu D, Patenaude Y, Fortin D :MR-pathologicalcomparison in F98-Fischer glioma model using a human gantry.Can J Neurol Sci 33 :86-91, 2006.

Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D,Neuwelt EA Osmotic blood-brain barrier disruptionchemotherapy for diffuse pontine gliomas.J neurooncol 29 :1-6,2005.

Mathieu D, Fortin D : Intracranial invasion of a basal cellcarcinoma of the scalp. Can J Neurol Sci 32:546-548, 2005.

Fortin D, Desjardins A, Benko A, Boudrias M: Blood-brain barrierdisruption enhanced chemotherapy in the treatment ofmalignant brain tumors: The Sherbrooke experience. Cancer103:12, 2606-2615, 2005.

Mathieu D, Lamarche J, Fortin D: The importance of a syngeneicsystem in animal malignant glioma implantation model. TheJournal of Applied Research 5;1: 17-25, 2005

Fortin D, Salamé J, Desjardins A, Benko A: Technical Modification inthe Intracarotid Chemotherapy and Osmotic Blood-BrainBarrier Disruption procedure to prevent the relapse ofcarboplatin-induced orbital pseudotumor. Am J Neuroradiol25:830-834, 2004

Fortin D: La barrière hémato-encéphalique : un facteur clé enneuro-oncologie. Rev Neurol 160 ;5: 523-532, 2004

Larouche A, Roy M, Kadhim H, Tsanaclis AM, Fortin D, Sébire G:Neuronal injuries induced by perinatal hypoxic-ischemic insultsare potentiated by prenatal exposure to lipopolysaccharide:animal model for perinatally acquired encephalopathy. DevNeurosci 27:134-142, 2004.

Fortin D, Adams R, Gallez A: A blood-brain barrier disruptionmodel eliminating the hemodynamic effects of ketamine. Can JNeurol Sci 2004;31:248-253, 2004

Kraemer D, Fortin D, Neuwelt EA : Chemotherapeutic doseintensification for treatment of malignant brain tumors:Recentdevelopments and future directions. Current Neurology andNeurosciences Reports 2:216-224, 2002

Fisher BJ, Naumova E, Leighton CC, Naumov GN, Kerklviet N, Fortin D,Macdonald DR, Cairncross JG, Bauman GS, Stitt L: Ki-67: aprognostic factor for low-grade glioma? Int J Radiat Oncol BiolPhys 15;52(4):996-1001, 2002

Kraemer D, McAllister L, Fortin D, Doolittle N, Neuwelt EA:Association of drug delivery and clinical outcomes in humannon-AIDS primary CNS lymphoma as a model to assess theimpact of total dose intensity delivered to the CNS. Neurosurgery48:1033-1041, 2001

Fortin D, Macdonald D, Stitt L, Cairncross JG: PCV chemotherapy foroligodendroglioma, anaplastic oligodendroglioma and mixedtumors: A retrospective analysis of 53 cases to determineprognostic factors for response and survival. Can. J. Neurol. Sci .28 :215-223, 2001

Doolittle N, Miner M, Hall W, Siegal T, Hanson J, Osztie E, McAllister L,Bubalo J, Kraemer D, Fortin D, Nixon R, Muldoon L and Neuwelt EA:Safety and Efficacy of a multi-center study using intraarterialchemotherapy in conjunction with osmotic opening of theblood-brain barrier for the treatment of malignant braintumors. CANCER 88 :637-647, 2000.

Fortin D, Osztie E, Neuwelt EA: Iatrogenic arterial spasm releivedby intra-arterial mannitol infusion. AJNR 21: 968-970, May 2000.

Fortin D, McCormick C, Remsen L, Nixon R, Neuwelt EA: Unexpectedneurotoxicity of etoposide phosphate when given incombination with other chemotherapeutic agents after bloodbrainbarrier modification to enhance delivery using propofolfor general anesthesia in a rat model. Neurosurgery 47 :199-207,2000.

Fortin D, McAllister L, Nesbit G, Doolittle N, Miner M, Hanson J,Neuwelt EA: Unusual cervical spinal cord toxicity associated withintra-arterial carboplatin, iv or ia etoposide phosphate, and ivcyclophosphamide in conjunction with osmotic blood brainbarrier disruption in the vertebral artery. AJNR 20:1794-1802,november/december 1999.

Fortin D, Cairncross JG, Hammond R: Oligodendroglioma: Anappraisal of recent data pertaining to diagnosis and treatment.Neurosurgery 45: 1279-1291, 1999.